Europe Migraine Treatment Market, By Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over the Counter), Drug Type (Branded and Generic), End-User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Europe Migraine Treatment Market Analysis and Size
Migraine is a common and debilitating brain illness. Headache accounts for 4.4 percent of all primary care visits, nearly 5% of all medical hospital admissions, and more than 20% of neurology outpatient consultations. Migraine affects approximately 20% of people at some point in their lives, according to epidemiological research, 4.5% of Western Europe's population suffers from headaches at least 15 days per month. The vast majority of medications on the market now are approved to treat the acute version of the illness with generic triptans serving as the primary therapy. With the advent of CGRP-based medicines and the acceptance of novel medication classes such as ditans, gepants and the reformulation of triptans for both chronic and episodic migraine, the industry is observing a shift in terms of significant R&D.
Data Bridge Market Research analyses that the migraine treatment market which is USD 1398.94 million in 2022, is expected to reach USD 3640.75 million by 2030, at a CAGR of 12.7% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Migraine Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over the Counter), Drug Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), GSK plc. (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Abbott (U.S.), Allodynic Therapeutics, LLC (U.S.), AOBiome (U.S.), AstraZeneca (U.K.), Aurobindo Pharma USA (U.S.), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S.), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S.), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Migraine is a debilitating neurological disease characterized by recurrent severe throbbing head pain attacks lasting more than three days. Migraine affects approximately 15% of the population over their lifetime with women (18%) being more affected than men (8%). It has been dubbed the "seventh disabler" due to its significant impact on patients' quality of life (QOL).
Migraine Treatment Market Dynamics
Drivers
• Increase in migraine prevalence and diagnosis
An enormous increase in migraine cases is a key factor fuelling market expansion. Additionally, the industry is gaining from better migraine treatment reimbursement rules and the increased need for precision medications. The market is expanding due to rising demand for electrical nerve stimulators used to treat migraines and the anticipated approval of new classes of late-stage pipeline medications with higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies.
- Significant progress is being made in the preventative treatment of chronic migraine
The important developments should force to revaluate how to treat this illness and encourage to keep an eye out for new developments in clinical science, and reminds that only a coordinated clinical and scientific management approach will increase the identification of chronic migraines. The distinction between phenotypic and biological indicators sheds light on areas of clinical governance that have gone unnoticed. It is up to ensure that cutting-edge and evolving therapy options, including OBT-A and anti-CGRP monoclonal antibodies, are fully utilized within a larger preventative culture to significantly reduce the societal, monetary and individual costs of this fatal illness.
Opportunities
- Growing awareness regarding migraine
The key factors influencing the growth of the Europe migraine treatment market in the near future are the rising prevalence of migraines and the variety of available treatments. Many organizations, such as the American Headache and Migraine Association, are working to increase public awareness of migraine by creating programmes and offering patient support. These efforts aim to increase understanding of the condition and associated headache conditions. Many vendors will invest in migraine medications' research and development (R&D) due to the growing incidence of migraines and unmet needs in the Europe migraine treatment market. As a result, during the forecast period of 2023 to 2030, the market for migraine treatment is anticipated to expand.
Restraints/Challenges
- Side effects associated with migraine treatment
The drop in clinical visits and procedural treatment of migraines due to social distance norms, limits of current migraine medicines and alternative therapies such as homoeopathy are anticipated to hamper the market growth in the forecast period of 2023 to 2030.
This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Migraine Treatment Market
The neurologic manifestations of COVID-19 suggest that the virus may have entered the nervous system through the olfactory groove or the bloodstream. There is compelling evidence that COVID-19 mortality is linked to cardiac and pulmonary diseases. Furthermore, migraine increases the burden of vascular diseases, putting migraine sufferers at a higher risk of poor COVID-19 outcomes. Acute COVID-19 symptoms such as fever, sleep disturbance, and dehydration may precipitate a migraine attack. COVID-19 headaches were described as pulsating, pressing, or stabbing in quality, were mostly bilateral, lasted longer, were resistant to analgesia and were more common in men. This makes migraine sufferers particularly vulnerable to the pandemic's chronic and indirect effects, such as low mood and post-viral fatigue. After the pandemic rising R&D spending resulting in massive pipeline products, as well as an increase in the prevalence of migraines with high unmet needs are all contributing to the growth of the migraine treatment market.
Recent Development
- In 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc., Rimegepant,introduced a calcitonin gene-related peptide (CGRP) receptor antagonist. The 75 mg dose of Rimegepant (available as an orally dissolving tablet) is suggested for marketing authorization for the acute treatment of migraine with or without aura in adults and the preventative treatment for episodic migraine in adults who experience at least four migraine attacks per month.
Europe Migraine Treatment Market Scope
The migraine treatment market is segmented on the basis of types, treatment, route of administration, product, distribution channel, drug type and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Episodic
- Migraine with Aura
- Chronic
- Others
Treatment
- Acute/Abortive Treatment
- Preventive/prophylactic Treatment
- Non-Pharmacological Therapies and Devices
Route of Administration
- Oral
- Parenteral
Product
- Prescription
- Over the Counter
Drug Type
- Branded
- Generic
End-User
- Hospitals
- Clinics
- Homecare
- Others
Distribution Channel
- Hospital-Based Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Migraine Treatment Market Regional Analysis/Insights
The migraine treatment market is analyzed and market size insights and trends are provided by country, type, treatment, route of administration, product, distribution channel, drug type and end-user as referenced above.
The countries covered in the migraine treatment market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Germany is dominating the Europe migraine treatment market due to the vast number of businesses present in the market and the strong emphasis placed on innovation and API production. Additionally, pharmaceutical industry investment has increased significantly in recent years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The migraine treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for migraine treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the migraine treatment market. The data is available for historic period 2011-2021.
Competitive Landscape and Migraine Treatment Market Share Analysis
The migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to migraine treatment market.
Some of the major players operating in the migraine treatment market are:
- Pfizer Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Amgen Inc. (U.S.)
- GSK plc. (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Abbott (U.S.)
- Allodynic Therapeutics, LLC (U.S.)
- AOBiome (U.S.)
- AstraZeneca (U.K.)
- Aurobindo Pharma USA (U.S.)
- Bausch Health Companies Inc. (Canada)
- Biohaven Pharmaceuticals (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Catalent, Inc (U.S.)
- Dr. Reddy’s Laboratories Ltd. (India)
- Impel Pharmaceuticals Inc. (U.S.)
- H. Lundbeck A/S (Denmark)
- Merck & Co., Inc (U.S.)
SKU-